Primary parotid non-Hodgkin's lymphoma:a clinical analysis of 21 patients
- VernacularTitle:原发性腮腺非霍奇金淋巴瘤21例临床分析
- Author:
Feng LI
;
Zhongyi GU
;
Mei HONG
- Publication Type:Journal Article
- Keywords:
Non-Hodgkin's lymphoma/radiotherapy;
Non-Hodgkin's lymphoma/chemotherapy;
Combined modality therapy;
Prognosis
- From:
Chinese Journal of Radiation Oncology
1992;0(04):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the clinical and pathological characteristics, treatment results and prognosis of primary parotid non-Hodgkin's lymphoma (NHL). Methods All of our 21 patients received operative resection first and were histologically comfirmed as having T-cell (intermediate grade) and 20 B-cell lineage (2 high grade, 6 intermediate grade ,12 low grade) including 7 mucosa-associatied lymphoid tissue (MALT) phenotype. Ann Anbor stages were 16 stage Ⅰ E and 5 stage Ⅱ E lesions. All patients were treated by radiotherapy,of them 11 were also given 2～6 cycle chemotherapy. Results The overall 5-year survival rate was 77.0%. All 5 patients who died did so of distant involvement. Conclusions Our data show that MALT lymphoma can be present as a primary paroid NHL,although it is not included in the Working Formulation. Low-dose radiotherapy is of choice in the treatment. Patients with intermediate or high grade NHL should be given multi-modality therapy.
